[go: up one dir, main page]

AR090605A1 - Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer - Google Patents

Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer

Info

Publication number
AR090605A1
AR090605A1 ARP130101105A ARP130101105A AR090605A1 AR 090605 A1 AR090605 A1 AR 090605A1 AR P130101105 A ARP130101105 A AR P130101105A AR P130101105 A ARP130101105 A AR P130101105A AR 090605 A1 AR090605 A1 AR 090605A1
Authority
AR
Argentina
Prior art keywords
disease
alzheimer
treatment
receiver antagonist
antagonist
Prior art date
Application number
ARP130101105A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR090605A1 publication Critical patent/AR090605A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta descripción se refiere a métodos de uso de la 2-(ciclohexilmetil)-N-{2-[(2S)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida en una terapia modificadora de la enfermedad para la enfermedad de Alzheimer, otras tauopatías y enfermedades neurodegenerativas relacionadas.
ARP130101105A 2012-04-06 2013-04-04 Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer AR090605A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305415.7A EP2647377A1 (en) 2012-04-06 2012-04-06 Use of an h3 receptor antagonist for the treatment of alzheimer's disease
US201361792635P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR090605A1 true AR090605A1 (es) 2014-11-26

Family

ID=46001073

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101105A AR090605A1 (es) 2012-04-06 2013-04-04 Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer

Country Status (17)

Country Link
US (2) US20150031893A1 (es)
EP (2) EP2647377A1 (es)
JP (1) JP6143842B2 (es)
KR (1) KR20150000490A (es)
CN (1) CN104363911A (es)
AR (1) AR090605A1 (es)
AU (1) AU2013244928B2 (es)
BR (1) BR112014024736A2 (es)
CA (1) CA2868481A1 (es)
ES (1) ES2618924T3 (es)
MX (1) MX354020B (es)
PL (1) PL2833887T3 (es)
RU (1) RU2014144615A (es)
SG (2) SG10201801200PA (es)
TW (1) TW201402119A (es)
UY (1) UY34734A (es)
WO (1) WO2013150150A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
JP2016529307A (ja) * 2013-09-09 2016-09-23 サノフイ アルツハイマー病の処置に使用するためのｈ３受容体アンタゴニスト
AU2020397508A1 (en) * 2019-12-05 2022-06-09 Axoltis Pharma Peptide compositions and methods for treating Tauopathies
CN114053289B (zh) * 2020-08-06 2023-06-27 北京箭牧科技有限公司 瑞德西韦在制备预防和治疗神经系统退行性疾病药物中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379493A2 (en) 2001-03-23 2004-01-14 Eli Lilly and Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
EP1554260A1 (en) 2002-10-22 2005-07-20 Glaxo Group Limited Aryloxyalkylamine derivatives as h3 receptor ligands
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
KR100897642B1 (ko) 2002-12-20 2009-05-14 글락소 그룹 리미티드 신경 장애 치료용 벤즈아제핀 유도체
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
CA2523431A1 (en) 2003-04-23 2004-11-25 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
US20060247227A1 (en) 2003-07-18 2006-11-02 Bailey James M Substituted piperidines as histamine h3 receptor ligands
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
RU2378257C2 (ru) 2004-03-01 2010-01-10 Актелион Фармасьютиклз Лтд Замещенные производные 1,2,3,4-тетрагидроизохинолина
GB0408083D0 (en) 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
WO2005123723A1 (en) 2004-06-18 2005-12-29 Glaxo Group Limited 3-cycloalkylbenzazepines as histamine h3 antagonists
GB0418267D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
EP1802307B1 (en) 2004-10-15 2008-02-27 Glaxo Group Limited Pyrrolidine derivatives as histamine receptors ligands
WO2006061193A1 (en) 2004-12-07 2006-06-15 Glaxo Group Limited Indenyl derivatives and use thereof for the treatment of neurological disorders
AU2006224440A1 (en) 2005-03-14 2006-09-21 Glaxo Group Limited Fused thiazole derivatives having affinity for the histamine H3 receptor
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
EP1790646A1 (fr) 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.
US20100120747A1 (en) 2006-06-23 2010-05-13 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
CL2008000597A1 (es) 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 6-(3-ciclobutil-2,3,4,5-tetrahidro-1h-benzo[d]azepin-7-il oxi)-n-metil nicotinamida, un estabilizante y un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
ATE554081T1 (de) 2007-09-06 2012-05-15 Glaxo Group Ltd Piperazinderivate mit affinität zum histamin-h3- rezeptor
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010023170A1 (en) 2008-08-29 2010-03-04 Glaxo Group Limited Dosage form comprising 1-isopropyl-4-{[4-(tetrahydro-2H-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1H-1,4-diazepine or a salt thereof
WO2010026113A1 (en) * 2008-09-03 2010-03-11 Evotec Neurosciences Gmbh Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
SG176645A1 (en) 2009-06-26 2012-01-30 Sanofi Sa Novel fumarate salts of a histamine h3 receptor antagonist
AR077859A1 (es) 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
WO2011051423A1 (en) 2009-11-02 2011-05-05 Glaxo Group Limited Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy
FR2976286B1 (fr) 2011-06-08 2013-05-24 Servier Lab 4-{3-[trans-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, son procede de preparation et les compositions pharmaceutiques qui le contiennent
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
EP2745876A1 (en) 2012-12-21 2014-06-25 Prous Institute for Biomedical Research, S.A. Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives
JP2016529307A (ja) * 2013-09-09 2016-09-23 サノフイ アルツハイマー病の処置に使用するためのｈ３受容体アンタゴニスト

Also Published As

Publication number Publication date
US9789102B2 (en) 2017-10-17
CN104363911A (zh) 2015-02-18
SG10201801200PA (en) 2018-04-27
BR112014024736A2 (pt) 2017-07-11
EP2833887B1 (en) 2016-12-28
EP2647377A1 (en) 2013-10-09
WO2013150150A1 (en) 2013-10-10
TW201402119A (zh) 2014-01-16
PL2833887T3 (pl) 2017-06-30
ES2618924T3 (es) 2017-06-22
SG11201406093VA (en) 2014-10-30
US20160101099A1 (en) 2016-04-14
US20150031893A1 (en) 2015-01-29
UY34734A (es) 2013-11-29
MX2014011992A (es) 2015-05-08
RU2014144615A (ru) 2016-05-27
AU2013244928A1 (en) 2014-10-30
JP2015516963A (ja) 2015-06-18
EP2833887A1 (en) 2015-02-11
KR20150000490A (ko) 2015-01-02
MX354020B (es) 2018-02-08
AU2013244928B2 (en) 2017-08-10
CA2868481A1 (en) 2013-10-10
JP6143842B2 (ja) 2017-06-07

Similar Documents

Publication Publication Date Title
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
CY1125068T1 (el) Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων
IL285843A (en) Ibrutinib for use in the treatment of chronic graft versus host disease
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
PL2766361T3 (pl) Pochodne 8-karbamoilo-2-(2,3-dipodstawionej piryd-6-ylo)-1,2,3,4,-tetrahydroizochinoliny jako środki wywołujące apoptozę do leczenia raka oraz chorób immunizacyjnych i autoimmunizacyjnych
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
UA107827C2 (xx) Антитіло до cd40
PE20191655A1 (es) Combinaciones farmaceuticas
EA201391351A1 (ru) Способы повышения эффективности folr1 терапии рака
AR095882A1 (es) Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
MX2015008777A (es) Crenolanib para el tratamiento de trastornos proliferativos que tienen flt3 mutado.
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
CL2012001293A1 (es) Uso del compuesto 2-(4-metilfenil)-6-(metil)quinolina para inhibor la agragacion de la proteina tau en una persona dque sufre alzheimer
CL2017000050A1 (es) Terapia de combinación para el cáncer
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
HRP20180531T1 (hr) Antagonisti serotoninskog 5-ht3 receptora za uporabu u liječenju površina vestibularnih lezija
SG11201601306QA (en) An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
EA201590823A1 (ru) 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора
AR090605A1 (es) Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer
EP2908805A4 (en) LEVODOPA FORMULATIONS FOR THE QUICK RELIEF OF MORBUS PARKINSON
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
CO6480943A2 (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3
EA201490938A1 (ru) Производные спиротиенопиранпиперидина в качестве антагонистов рецептора orl-1 для применения для лечения алкогольной зависимости и злоупотребления алкоголем
DK3402537T3 (da) Kvantitativ PET-afbildning af vævsfaktorekspression under anvendelse af 18-F mærket, aktiv positions-inhiberet faktor VII
EA201491226A1 (ru) НОВОЕ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ p75

Legal Events

Date Code Title Description
FB Suspension of granting procedure